Related Experiment Videos
Engineering of human complement component C3 for catalytic inhibition of complement
Johanna Kölln1, Reinhard Bredehorst, Edzard Spillner
1Institut für Biochemie und Lebensmittelchemie, Abteilung für Biochemie und Molekularbiologie, Universität Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany.
Immunology Letters
|March 26, 2005
Summary
Researchers engineered a novel human C3 protein derivative that effectively neutralizes complement activity. This derivative, with a minimized non-human C345C domain, shows promise for treating complement-mediated diseases.
Area of Science:
- Immunology
- Biochemistry
- Drug Discovery
Background:
- The complement system is crucial in innate immunity but implicated in various pathologies.
- Current complement inhibitors often act by blocking function, which can lead to adverse effects.
Purpose of the Study:
- To develop a novel human C3 derivative for complement-mediated diseases.
- To reduce the immunogenicity of a previously developed C3 derivative by minimizing non-human sequences.
- To identify essential domains for stable C3 convertase formation.
Main Methods:
- Engineering human C3 (hC3) derivatives by substituting C-terminal sequences with cobra venom factor (CVF) sequences.
- Evaluating the functional complement-obliterating capacity of derivatives in vitro.
- Analyzing the role of specific domains, particularly the NTR/C345C motif, in C3 convertase stability.
Main Results:
- A derivative was created with a significantly reduced non-human portion, retaining complement-obliterating activity.
- The conserved NTR/C345C motif was identified as a key domain for C3 convertase regulation and half-life.
- The optimized derivative exhibits 96% identity to human C3, suggesting reduced immunogenicity.
Conclusions:
- The C345C domain plays a critical role in regulating C3 convertase stability and function.
- A highly humanized C3 derivative with a minimized non-human motif is a promising therapeutic candidate for complement-mediated diseases.